PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33397228-0	2021	Different Induction Effects of Praziquantel Racemate and Enantiomers on the Enzyme CYP3A4 Mediated by Pregnane X Receptor and Its Variants.	Praziquantel	31-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89	
33397228-3	2021	OBJECTIVE: The purpose of this study was to investigate the possible different induction effects of CYP3A4 by PZQ racemate and enantiomers via the pregnane X receptor (PXR) and the effect of PXR polymorphism on the induction potency of PZQs.	Praziquantel	110-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-106	
33397228-8	2021	The induction ability of CYP3A4 mediated by PXR activation by PZQ racemate and its enantiomers were statistically different between the same PXR group and different PXR groups.	Praziquantel	62-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-31	
18021336-10	2007	CONCLUSION: Ketoconazole co-administration alters the pharmacokinetics of praziquantel in humans, possibly through inhibition of CYP3A, particularly CYP3A4, first-pass metabolism of praziquantel.	Praziquantel	74-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-134	
18021336-10	2007	CONCLUSION: Ketoconazole co-administration alters the pharmacokinetics of praziquantel in humans, possibly through inhibition of CYP3A, particularly CYP3A4, first-pass metabolism of praziquantel.	Praziquantel	74-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-155	
18021336-10	2007	CONCLUSION: Ketoconazole co-administration alters the pharmacokinetics of praziquantel in humans, possibly through inhibition of CYP3A, particularly CYP3A4, first-pass metabolism of praziquantel.	Praziquantel	182-194	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-134	
17357589-0	2006	Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4).	Praziquantel	21-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-62	
17357589-0	2006	Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4).	Praziquantel	21-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-71	
17357589-9	2006	In vitro model of PZQ biotransformation was created by using human cytochrome P-450 3A4 expressed in Eschelichia coli and Saccharomyces cerevisiae.	Praziquantel	18-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-87	
12426514-2	2002	The CYP3A isoforms are likely to be major enzymes responsible for praziquantel metabolism.	Praziquantel	66-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-9	
32700798-8	2020	Metabolism of R-PZQ was mainly catalyzed by CYP1A2 and CYP2C19, whereas metabolism of S-PZQ was mainly by CYP2C19 and CYP3A4.	Praziquantel	86-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124	
32700798-9	2020	Based on metabolic CLint obtained through formation of hydroxylated metabolites, CYP3A4 was estimated to contribute 89.88% to metabolism of S-PZQ using SIMCYP  IVIVE prediction.	Praziquantel	140-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87	
32700798-10	2020	Reanalysis of samples from a human PZQ-ketoconazole (KTZ) drug-drug interaction pharmacokinetic study confirmed these findings in that KTZ, a potent inhibitor of CYP3A, selectively increased area under the curve of S-PZQ by 68% and that of R-PZQ by just 9%.	Praziquantel	215-220	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	162-167